title: Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
abstract: We evaluated the relevance of human cytomegalovirus (HCMV) monitoring with quantitative real-time polymerase chain reaction in 42 consecutive HCMV positive liver transplant patients, and we analyzed the factors that determined the treatment of the first episode of HCMV DNAemia. No patients received anti-HCMV prophylaxis. HCMV infection monitoring was assessed every 2 weeks until day 90 and thereafter at every 3 to 4 weeks until day 180. HCMV infection was detected among 27 patients (64%, ie, 92/380 samples). Of these, 12 had their first HCMV DNAemia treated with IV gancyclovir (group I), whereas the other 15 patients were not treated (group II). Immunosuppressive treatment was not modified in cases of HCMV DNAemia. The median time between transplantation to the first CMV DNAemia was 37 days in group I and 52 days in group II (NS). Median HCMV viral load, whatever the treatment group and whatever the time of DNAemia, was 3 log copies/mL (0.48 to 5.80). Median HCMV viral load of the first positive DNAemia was 3.45 log copies/mL (1.69 to 5.80) in group I and 2.70 log copies/mL (1.15 to 3.94) in group II (P = .01). Even though liver enzymes were increased in almost all patients presenting with HCMV infection, comparison of liver-enzyme levels and hematological parameters between the two groups at first HCMV viremia showed that alkaline phosphatase levels were significantly higher (P = .0011) and hemoglobin levels were significantly lower in group I patients (P = .0443). The only factor that predicted treatment for the first episode of HCMV DNAemia was an alkaline phosphatase level >150 UI/mL at the time of the first HCMV reactivation [odds ratio 20 (1.96 to 203.3); P = .01].
authors.affiliation: Multiorgan Transplant Unit, University Hospital, CHU Rangueil, 1 avenue Jean Poulhès, TSA 50032, 31059 Toulouse cedex 9, France.
authors.forename: A
authors.initials: A
authors.lastname: Pillet
authors.forename: C
authors.initials: C
authors.lastname: Mengelle
authors.forename: G
authors.initials: G
authors.lastname: Basse
authors.forename: D
authors.initials: D
authors.lastname: Ribes
authors.forename: N
authors.initials: N
authors.lastname: Kamar
authors.forename: F
authors.initials: F
authors.lastname: Muscari
authors.forename: L
authors.initials: L
authors.lastname: Lavayssière
authors.forename: B
authors.initials: B
authors.lastname: Suc
authors.forename: L
authors.initials: L
authors.lastname: Esposito
authors.forename: J-M
authors.initials: JM
authors.lastname: Peron
authors.forename: L
authors.initials: L
authors.lastname: Rostaing
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000235:genetics / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000235:genetics; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000821:virology*; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D004279:DNA, Viral; D007166:Immunosuppressive Agents; D012367:RNA, Viral; D016559:Tacrolimus